ALDH1B1 and osteosarcoma: In our study, we found that the inhibition of ALDH1B1 expression could increase the sensitivity of OS cells to chemotherapy (doxorubicin), suggesting that ALDH1B1 could be served as a therapeutic target to reverse chemotherapy resistance and combination therapies could be explored in osteosarcoma clinical trials.